(Q42952867)

English

Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps

scientific article published on 26 November 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps (English)

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

1 reference

ChEBI release 2020-05-28

inflammatory bowel diseases

1 reference

based on heuristic

inferred from title

Escherichia coli

1 reference

based on heuristic

inferred from title

Brian P Bosworth

3

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

6

object named as

Josee Harel

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

author name string

Vishesh Kothary

1

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Ellen J Scherl

2

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Zhi-Dong Jiang

4

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Herbert L Dupont

5

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Kenneth W Simpson

7

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Belgin Dogan

8

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

language of work or name

0 references

publication date

26 November 2012

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Antimicrobial Agents and Chemotherapy

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

57

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

2

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

811-817

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

The role of bacteria in the pathogenesis of ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Multidrug Resistance Is Common in Escherichia coli Associated with Ileal Crohnʼs Disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Characterizations of clinical isolates of clostridium difficile by toxin genotypes and by susceptibility to 12 antimicrobial agents, including fidaxomicin (OPT-80) and rifaximin: a multicenter study in Taiwan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Rifaximin in the treatment of inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Biologic properties and clinical uses of rifaximin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Efficacy and tolerability of immunoregulators and antibiotics in fistulizing Crohn's disease: a systematic review and meta-analysis of placebo-controlled trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Bile acids improve the antimicrobial effect of rifaximin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Long‐Term Antibiotic Treatment for Crohn's Disease: Systematic Review and Meta‐Analysis of Placebo‐Controlled Trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Rifaximin for maintenance therapy in antibiotic-dependent pouchitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Development of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Culture independent analysis of ileal mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in Crohn's disease involving the ileum

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Progress in targeting bacterial transcription

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Inhibitors of efflux pumps in Gram-negative bacteria

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Antibiotics for inflammatory bowel disease: do they work?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Selected arylpiperazines are capable of reversing multidrug resistance in Escherichia coli overexpressing RND efflux pumps

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Influence of rifaximin treatment on the susceptibility of intestinal Gram-negative flora and enterococci

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Rifaximin versus ciprofloxacin for the treatment of traveler's diarrhea: a randomized, double-blind clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Structural mechanism for rifampicin inhibition of bacterial rna polymerase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Antibiotic susceptibility profiles of Escherichia coli strains lacking multidrug efflux pump genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Compensatory evolution in rifampin-resistant Escherichia coli

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Rapid and simple determination of the Escherichia coli phylogenetic group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

In vitro activity and fecal concentration of rifaximin after oral administration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers' diarrhea

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

RAPD (arbitrary primer) PCR is more sensitive than multilocus enzyme electrophoresis for distinguishing related bacterial strains

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

26 May 2018

Fitness and molecular mechanisms of resistance to rifaximin in in vitro selected Escherichia coli mutants.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

16 August 2018

Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

16 August 2018

Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

16 August 2018

Molecular and phenotypic traits of in-vitro-selected mutants of Bifidobacterium resistant to rifaximin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

16 August 2018

Effect of 1-(1-naphthylmethyl)-piperazine, a novel putative efflux pump inhibitor, on antimicrobial drug susceptibility in clinical isolates of Escherichia coli

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

16 August 2018

Effect of the efflux pump inhibitor Phe-Arg-beta-naphthylamide on the MIC values of the quinolones, tetracycline and chloramphenicol, in Escherichia coli isolates of different origin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

16 August 2018

Mucosal flora in inflammatory bowel disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

16 August 2018

Rifaximin in patients with moderate or severe ulcerative colitis refractory to steroid-treatment: a double-blind, placebo-controlled trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

16 August 2018

Genetic and proteomic characterization of rifaximin resistance in Bifidobacterium infantis BI07

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3553721

3 November 2018

Rifaximin for active ulcerative colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23183443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23183443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sero-reactivity to microbial components in Crohn's disease is associated with disease severity and progression, but not NOD2/CARD15 genotype

1 reference

https://pubmed.ncbi.nlm.nih.gov/23183443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A Meta-Analysis of Antibiotic Therapy for Active Ulcerative Colitis

1 reference

https://pubmed.ncbi.nlm.nih.gov/23183443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Rapid disappearance from the intestinal tract of bacteria resistant to rifaximin

1 reference

https://pubmed.ncbi.nlm.nih.gov/23183443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunocytochemical evidence of Listeria, Escherichia coli, and Streptococcus antigens in Crohn's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23183443

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1128/AAC.02163-12

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42952867&oldid=1974366116"